Coya Therapeutics Stock Down 3.79% Since IPO
Coya Therapeutics Stock Down 3.79% Since IPO
Coya Therapeutics (NASDAQ:COYA) opened up its shares for public trading for the first time since it filed for IPO in November 2022. The company agreed to initially offer 3.05 million shares to the public at $5.00 per share. On its first day of trading, the stock decreased 3.79% from its opening price of $4.75 to its closing price of $4.57.
Coya Therapeutics Performance On First Day of Trading
About Coya Therapeutics and It's IPO
Coya Therapeutics, Inc is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation.
For its IPO, COYA agreed to offer 3.05 million shares at a price of $5.00 per share, with an insider lock-up period of 180 days, ending on June 27, 2023.
An insider lock-up period is a period of time after a company first goes public where major shareholders are not allowed to sell their shares. The insider lock-up period makes sure that the market does not get oversupplied with shares of the company.
Traders may short the stock leading up to the lockup-period expiration date in hopes that the price will fall due to an increase in supply of shares. Retail traders should be watching this stock's short interest as it moves closer to lockup expiration.
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Coya Therapeutics (NASDAQ:COYA) opened up its shares for public trading for the first time since it filed for IPO in November 2022. The company agreed to initially offer 3.05 million shares to the public at $5.00 per share. On its first day of trading, the stock decreased 3.79% from its opening price of $4.75 to its closing price of $4.57.
科雅治療 (納斯達克:COYA)自 2022 年 11 月申請首次公開招股以來首次開放其股票進行公開交易。該公司同意最初以每股 5.00 美元的價格向公眾發售 350 萬股股份。在交易首日,股票由 4.75 美元的開盤價下跌 3.79% 至收市價 4.57 美元。
Coya Therapeutics Performance On First Day of Trading
Coya 治療學在交易的第一天表現
About Coya Therapeutics and It's IPO
關於科雅治療和它的 IPO
Coya Therapeutics, Inc is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation.
Coya Therapitics, Inc 是一家臨床階段的生物技術公司,開發專有治療方法,專注於監管 T 細胞(「Tregs」)的生物學和潛在治療優勢,以針對全身性炎症和神經炎症。
For its IPO, COYA agreed to offer 3.05 million shares at a price of $5.00 per share, with an insider lock-up period of 180 days, ending on June 27, 2023.
在首次公開招股方面,COYA 同意以每股 5.00 美元的價格發售 350 萬股股票,內幕鎖倉期為 180 天,截至 2023 年 6 月 27 日。
An insider lock-up period is a period of time after a company first goes public where major shareholders are not allowed to sell their shares. The insider lock-up period makes sure that the market does not get oversupplied with shares of the company.
一個 內幕鎖定期 是公司首次上市後的一段時間,主要股東不得出售其股份。內幕鎖定期確保市場不會因公司的股份而過度供應。
Traders may short the stock leading up to the lockup-period expiration date in hopes that the price will fall due to an increase in supply of shares. Retail traders should be watching this stock's short interest as it moves closer to lockup expiration.
交易者可能會在鎖定期限到期日之前做空股票,希望由於股票供應量的增加,價格將下跌。零售交易者應該關注該股票的短期利息,因為它接近鎖定到期日。
See also: Benzinga's Most Shorted Stocks
另請參閱: 本辛加最短空的股票
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由 Beninga 的自動化內容引擎生成,並由編輯審查。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧